Weill Cornell Medicine investigators introduced a versatile gene‑switch system that uses a non‑toxic, clinically used antiviral molecule to control expression of target genes in cells. The technology—designed to enable researchers to switch genes on or off with temporal precision—reduces reliance on toxic small molecules and promises broader adoption in preclinical gene‑therapy research. Developers said the platform could accelerate functional genomics studies and improve safety controls in experimental gene therapies by enabling reversible, tightly regulated gene expression. The tool may be rapidly adopted across academic and industry labs seeking safer inducible systems for translational research.